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Abstract
The influenza A H7N9 virus outbreak in Eastern China in the spring of 2013 represented a novel, emerging avian influenza
transmission to humans. While clinical and microbiological features of H7N9 infection have been reported in the literature,
the current study investigated acute cytokine and antibody responses in acute H7N9 infection. Between March 27, 2013 and
April 23, 2013, six patients with confirmed H7N9 influenza infection were admitted to Drum Tower Hospital, Nanjing, China.
Acute phase serum cytokine profiles were determined using a high-throughput multiplex assay. Daily H7 hemagglutinin
(HA)-specific IgG, IgM, and IgA responses were monitored by ELISA. Neutralizing antibodies specific for H7N9 viruses were
determined against a pseudotyped virus expressing the novel H7 subtype HA antigen. Five cytokines (IL-6, IP-10, IL-10, IFNc,
and TNFa) were significantly elevated in H7N9-infected patients when compared to healthy volunteers. Serum H7 HA-
specific IgG, as well as IgM and IgA responses, were detected within 8 days of disease onset and increased in a similar
pattern during acute infection. Neutralizing antibodies developed shortly after the appearance of binding antibody
responses and showed similar kinetics as a fraction of the total H7 HA-specific IgG responses. H7N9 infection resulted in
hallmark serum cytokine increases, which correlated with fever and disease persistence. The novel finding of simultaneous
development of IgG, IgM, and IgA responses in acute H7N9 infection points to the potential for live influenza viruses to elicit
fast and potent protective antibodies to limit the infection.
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Introduction
An emerging Type A influenza H7N9 infection in humans,
which started in early 2013, has continued in China and represents
another major threat to global health [1–20]. H7N9 has a
mortality rate of 32.4% [21]. Multiple environmental and/or
virological changes may have contributed to this outbreak [22,23].
While the clinical symptoms and features of isolated H7N9 virus
strains have recently been described, information on early immune
responses in acutely H7N9-infected patients is limited [5–7,24–
27]. Given the importance of antibody responses in protection
immunity against influenza and the role of cytokines in modulating
innate immune responses in patients infected with influenza
viruses, the current report analyzed serum H7 HA-specific binding
antibody responses starting within 6–11 days after onset of fever in
H7N9 patients, the development of neutralizing antibodies, and
serum levels of specific cytokines in a cohort of six H7N9-infected
patients admitted to a hospital in Nanjing during the peak of the
2013 outbreak. Due to limited knowledge in the existing literature
regarding acute immune responses to an outbreak of a novel avian
influenza in humans, information described in this report may be
useful for a better understanding on the development of acquired
and innate immunities early after avian influenza infection.
Materials and Methods
Patient information and sample collection
Between March 27, 2013 and April 23, 2013, six patients were
admitted to the Nanjing Drum Tower Hospital (NDTH) (Table 1)
with confirmed influenza H7N9 virus infection via detection of
viral RNA with real-time PCR [7]. Sputum and blood samples
were collected as part of routine clinical management. Blood
samples were collected from ten healthy volunteers (five males and
five females; aged 32–59 years) as controls. The study was
PLOS ONE | www.plosone.org 1 July 2014 | Volume 9 | Issue 7 | e101788
reviewed and approved by the Ethics Committee at Nanjing
Drum Tower Hospital and written informed consent was obtained
from each participant or their legal representative.
Influenza H7N9 viral RNA detection
RNA was extracted from sputum samples in TRIzol per
manufacturer’s instructions. H7 hemagglutinin (HA) and N9
neuraminidase (NA) genes were detected by fluorescence reverse
transcription (RT) PCR Detection kits (BioPerfectus Technologies,
Taizhou, Jiangsu Province, China) provided by Nanjing CDC on
the ABI 7500 (Applied Biosystems). Primers and protocols were
prepared according to those provided by the WHO Collaborating
Center in Beijing [7].
Serum cytokine/chemokine assays
Frozen sera were thawed for cytokine/chemokine measure-
ments using the Human Magnetic Cytokine/Chemokine Bead
Panel –15 Plex (Millipore Corporation, Billerica, MA, USA) on
the MAGPIX instrument (Luminex Corporation, Austin, TX,
USA). The multiplex assay measures 15 serum cytokines,
chemokines, and other immune biomarkers (GM-CSF, TNF-a,
IFN-c, IL-1RA, IL-1b, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12P70,
IL-17A, IP-10, MCP-1, and sCD40L), per manufacturer’s
instructions.
H7-specific binding antibodies
ELISA was conducted to measure H7 HA-specific IgG, IgA,
and IgM responses in H7N9-infected patients. Briefly, 96-well flat-
bottom plates were coated with recombinant H7 HA antigen of
H7N9 A/Zhejiang/U01/2013, which was produced from DNA
vaccine transfected 293T cells (-Haiyuan Protein Biotech, Inc.,
Taizhou, China) [28]. Plates were incubated with 100 ml
horseradish peroxidase (HRP)-conjugated anti-human IgG, IgA,
or IgM (Southern Biotech) and developed with 3,3,5,5-tetra-
methylbenzidine (TMB) solution (Sigma, St. Louis, MO). Data
were presented as the OD value (for daily IgG) or titer of IgG, IgA,
and IgM. The end titration titer was determined as the highest
serum dilution that had an OD reading twice above that of the
negative control serum.
Influenza H7 pseudotyped virus production and
neutralization assays
Levels of H7 HA-specific protective antibodies were measured
using a pseudotyped virus system, as previously reported [29–31].
293T cells with 80% confluence in 10 cm dishes were co-
transfected with 1.2 mg HA-expressing plasmid (pJW4303/H7-
HA ZJU01.wt), 0.3 mg NA-expressing plasmid (pJW4303/N9-NA
SH02.wt), 13.5 mg HIV-1 replicon DNA (pNL4-3.LucR-E-), with
deletion of envelope gene and insertion of the firefly luciferase
gene in the Nef-encoding region, and 75 ml PEI (1 mg/ml)
transfection reagent (Polysciences, Eppelheim, Germany) in 750 ml
DMEM. Six hours later, the transfected cell culture was changed
to freshly-made FBS-free DMEM medium. The supernatant was
harvested 72 hours later, filtered and treated with Trypsin-TCPK
(Sigma) at a final concentration of 40 mg/ml, then stopped with
Trypsin inhibitor (Sigma) at 10 mg/ml. The median tissue culture
infectious dose (TCID50) of H7 pseudovirus was titrated in 293A
cells and stored at 280uC until use.
A neutralization assay was conducted using the above
pseudotyped virus. Briefly, serial dilutions of patient serum
samples (in duplicate) were incubated with H7 pseudovirus (200
TCID50 in 50 ml growth medium per well) in a 96-well cell culture
plate; 293A cells (16104), in 100 ml growth medium, were added
to each well. After incubation, cells were lysed and RLU was
measured and 50% inhibitory dose (ID50) was determined.
Data analysis
Student’s t-test was used to determine statistical significance of
peak cytokine levels in patient sera. Spearman’s Rank-Order
Correlation was used to determine the correlation between fever
and cytokine levels in patients infected with H7N9.
Results
During the initial H7N9 outbreak in the spring of 2013, six
patients with confirmed H7N9 infection were admitted to the
Nanjing Drum Tower Hospital (Table 1) [3,32]. Four (66%) had a
reported history of poultry contact and most had early onset upper
respiratory symptoms. All had fever and were admitted to the
hospital after varying lengths of fever (six to 11 days). Within the
first week of admission, elevated body temperature, ranging from
38.5uC to 41uC, was observed in all six patients, and subsequently
returned to normal levels following antiviral therapy and other
treatment (Fig. 1). All six patients survived during the study period;
four were discharged within the first 1–2 months of admission and
two stayed longer than two months (Table 1). According to the
medical records, Patient (Pt) #1 also had a co-morbidity of
chronic hepatitis B virus infection and Pt #3 had resected thyroid
carcinoma and leukocytosis, furthermore, both patients also had
the complication with bacterial pneumonia, which contributed to
their longer hospitalization after clearance of H7N9 infection.
Simultaneous measurement of serum cytokine profiles during
the acute phase of H7N9 infection showed five were significantly
elevated in H7N9-infected patients compared to healthy human
controls (Fig. 2A). The other nine cytokines and chemokines were
Table 1. Basic characteristics of H7N9-infected patients.
H7N9-infected patients
PT-1 PT-2 PT-3 PT-4 PT-5 PT-6
Age 45 48 61 30 54 36
Gender F F F M M M
Occupation Poultry worker Farmer House wife Chef Clerk Poultry retailer
Poultry contact history Yes Yes Yes No No Yes
Admission (days after fever onset) 9 11 8 8 9 6
Hospital Stay (days) .60 35 .60 38 28 22
doi:10.1371/journal.pone.0101788.t001
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also elevated in H7N9-infected patients but not significantly (p.
0.05) (Fig. 2B). In contrast, sCD40L serum levels were significantly
suppressed in H7N9-infected patients (Fig. 2C).
Two patients (#1 and #3), who experienced prolonged clinical
symptoms and a longer hospital stay, showed persistently elevated
TNFa, IL-6, IL-10, and IP-10 (Fig. 3B–3E); furthermore, one
patient (#3) also had elevated IFNc for an extended period of time
(Fig. 3A). On the other hand, two patients (#5 and #6), who had
the quickest recovery and the shortest hospital stays, demonstrated
a quick return to normal of all elevated cytokines. One patient
(#6), who was discharged first among this cohort, did not have
elevated serum IL-6 (Fig. 3C). Further analysis on temperature
and cytokine levels from the same day showed that among the five
significantly elevated cytokines, four (IFNc, IL-6, IL-10, and IP-
10) correlated with increases in body temperature (Fig. 4A, 4C–
4E); no such relationship was observed for TNFa (Fig. 4B).
The temporal relationship between viral clearance, highest
fever, and peak major serum cytokines is shown in Fig. 5. It took a
median of 24 days (range 11–36 days) to clear the H7N9 virus
based on RT-PCR results of sputum (Fig. 5). The highest fever
elevation occurred in the first 15 days of fever onset. Significantly
elevated serum cytokines mostly occurred before complete
clearance of H7N9. Peak IFNc levels also occurred quite early
although for some patients, peak occurred at a later time.
Serum antibody responses specific to the HA antigen of H7N9
were monitored daily from the day of admission until the time of
discharge or at end of the current study period (day 60 after onset
of fever) (Fig. 6). Three patients (#1–#3) had clearly elevated H7
HA-specific antibodies in their sera on the day of admission while
three other patients (#4–#6) showed a daily increase in H7 HA-
specific antibodies starting on the day of admission (Fig. 6). This
finding suggested that the first three patients may have had a
longer period of H7N9 infection before being admitted although,
based on the onset of fever, the length of their pre-admission
period was relatively similar to the other three patients (Table 1). It
is possible that these patients may have had other clinical
symptoms before developing fever so the onset of viral infection
may have been longer before their admission. Interestingly,
Patients #1–#3 also had a prolonged clinical course and stayed
in the hospital longer (beyond Day 50 from onset of fever)
compared with the other three patients (with stays between 28–46
days after onset of fever) (Fig. 1). Early hospitalization with specific
treatment may contribute to a better clinical outcome.
Detailed analysis was conducted to determine isotype specificity
of H7 HA antibody responses in infected patients (Fig. 7). For this
analysis, antibody titers were determined by the end titration of
serum against H7 HA antigen coated in ELISA plates; daily titers
were determined only within the first 20 days of fever onset
followed by titers determined every 10 days for the remaining
period of hospitalization. The same two subgroups were observed
as in the early days after admission. Patients #1–#3 had an H7
HA-specific IgG titer between 1:104 and 1:105, while the other
three patients had low or below detectable levels of H7 HA-
specific IgG responses. In the latter subgroup, H7 HA-specific IgG
titers rose daily from the day of admission and, within one week,
reached the same peak level IgG as the first three patients. Because
the end titration titer approach was used in this analysis, H7 HA-
specific IgG titers continued to rise even in the first three patients,
providing evidence that these patients were also newly infected
and might have a longer pre-admission infection course.
Further measurement of serum H7 HA-specific IgM (blue
curve) and IgA (green curve) antibody responses revealed similar
kinetics as observed for IgG (black curve) (Fig. 7). Several
important findings are noted. First, IgM and IgA rose almost at
Figure 1. Daily temperature monitoring of H7N9 patients after admission. Daily body temperature of individual patients (PT-1 to PT-6) was
recorded. The dashed line in each graph indicates the normal body temperature, 37.5uC, as the cutoff for fever.
doi:10.1371/journal.pone.0101788.g001
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the same time as IgG, which was not expected. Second, H7 HA-
specific IgA titer responses were lower than IgG titers in most
patients but IgM titers were similar to IgG responses. Third, after
maintaining peak titers for no more than 20–30 days from the
onset of fever, levels for all antibody isotypes (IgG, IgM, and IgA)
started to drop. Typically, the magnitude of titer drop is about one
to two logs. Because the current report only focused on acute
immune responses, long-term H7 HA-specific antibody responses
are currently unknown.
Neutralizing antibodies (red curve) against the H7N9 virus were
measured in the current study (Fig. 7) using a pseudotyped virus
system. Neutralizing antibodies developed at a later time point
than IgG binding antibodies in four patients except #1 and #2
who had higher level binding antibodies early in the study.
However, the delay in developing neutralizing antibodies was only
a few days. Neutralizing antibody titers are, in general, lower than
IgG binding antibodies as expected but it may also reflect the
difference in assay methods. However, the trends of HA-specific
IgG and neutralizing antibody kinetics were very similar. Although
not all H7 HA IgG are protective, the levels of HA-specific IgG
titers in patient sera may be useful to predict the levels of
protective antibody. Interestingly, neutralizing antibody levels did
not drop over time in four patients (#3–#6). This may suggest
that functional antibodies are high affinity antibodies, which are
products of mature B cells or plasma cells. Levels of these cells may
be better maintained over time compared to less mature B cells.
Discussion
H7N9 is a novel emerging avian influenza infection with a high
human mortality rate. Innate immune responses play a key role in
the pathogenesis and control of influenza infection. In the current
study, we employed updated assay methodology to investigate
serum levels of 15 key cytokines, chemokines, and immune
modulators in H7N9-infected patients. Five (IL-6, IP-10, IL-10,
IFNc, and TNFa) were significantly elevated in H7N9-infected
patients compared to age-matched healthy individuals. Although
reports have demonstrated that the cytokine responses could be
related to H7N9 pathogenicity in infected mice[33,34], there are
only a few reports about cytokine responses in infected patients.
Our data are consistent but not identical to findings from these
reports in the literature that studied cytokine and chemokine levels
in H7N9-infected patients[8,35–37]. In one study, IL-6 and IP-10
were significantly elevated in H7N9-infected patients, but IL-10,
IFNc and TNFa were not when compared to healthy controls [8].
Figure 2. The peak serum cytokine and chemokine levels in H7N9 patients and healthy donors. ‘‘P’’ or ‘‘H’’ under each column indicates
‘‘H7N9 patients’’ or ‘‘healthy donors’’, respectively. Three patterns of cytokine/chemokine profiles are shown: significantly elevated (A), elevated but
not significant (B) or significantly suppressed (C) in H7N9-infected patients when compared to healthy donors. Each bar represents the geometric
mean of each serum cytokine/chemokine concentration with standard error of in six patients or eight healthy donors. Statistical significance is
indicated when the p value is less than 20.05between the patient and healthy donor groups.
doi:10.1371/journal.pone.0101788.g002
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On the other hand, that study showed a significant elevation of IL-
2 and IL-17, which were also elevated in our study but not
significantly [8]. Han et al. demonstrated that the fatal outcomes
and disease severity were significantly associated with high TNFa
levels in sera while the degree of liver damage were significantly
correlated with their serum levels of Th2 cytokines IL-4 and IL-9
[36] whiles others demonstrated that the levels of serum IL-6, IL-
8, C-reactive protein and MIP-1b were associated with the
diseases severity [35,37]. Because different commercial cytokine
detection kits were used in various studies, some discrepancies are
not unexpected, but data from these studies confirm that increases
of IL-6 and IP-10 are prominent in H7N9-infected patients.
Measurement of serum cytokine profiles in other avian
influenza infection, such as H5N1 or the 2009 pandemic H1N1
influenza (pH1N1), has been reported in a few studies, but highly
sensitive and high-throughput technology was not used to directly
measure a large panel of cytokines in acute influenza infection.
However, a strong correlation between elevation of IL-6 and IL-10
and severe pH1N1 infection was noted [38]. In a separate study,
IL-6, TNFa, IL-8, and IL-15 were significantly higher in the group
with severe pH1N1 infection when a panel of nine serum cytokines
was analyzed [39]. IL-10 was not included in this study. The role
of IL-6, was further confirmed when IL-6 serum concentrations
were significantly elevated in patients who required critical care
support compared to patients who did not [40].
IL-6, IFNc, and TNFa were also elevated in fatal human avian
influenza H5N1 infection [41]. Serum IL-6, IL-10, and IFNc
continued to increase during the clinical course; IP-10 and MCP-1
remained at a high level from the beginning of infection [8]. In an
in vitro study using human primary alveolar and bronchial
epithelial cells, H5N1 viruses were more potent inducers of IL-6,
IP-10, RANTES, and IFNb compared to seasonal human H1N1
viruses [42].
Taken all together, it appears that IL-6 is elevated in all types of
influenza infection and IP-10 is another potentially important
cytokine in influenza infection. IL-6 is a proinflammatory cytokine
of innate immunity [43], which is secreted by T cells and
macrophages to stimulate immune responses during infection. IL-
6 also supports the growth of B cells and is antagonistic to
regulatory T cells. Consistent with clinical reports, IL-6 was also
increased during the host response to pH1N1 infection in mice,
supporting the idea that IL-6 is an indicator of disease severity for
influenza infection.
IP-10 (Interferon gamma-induced protein 10) is a chemokine
produced in macrophage and dendritic cells. IP-10 may serve
several roles, such as chemoattraction for monocytes/macrophag-
es, T cells, NK cells, and promotion of T cell adhesion to
endothelial cells. High levels of IP-10 were found in hepatitis C
virus (HCV)- or human immunodeficiency virus type 1 (HIV-1)-
infected patients who did not respond well to anti-viral treatment
[44–46].
Three other significantly elevated cytokines in our study have a
wide range of biological functions. IFNc is a cytokine of innate and
adaptive immunity that activates macrophages, differentiates Th1
from T cells, inhibits the Th17 pathway, and controls intracellular
pathogens [47]. TNFa is a cytokine of innate immunity and its
Figure 3. The kinetics of significantly elevated cytokines in H7N9-infected patients after admission. The kinetics of five significantly
elevated serum cytokine concentrations is plotted for individual patients (PT-1–PT-6) during the time of hospitalization: IFN-c (A), TNF-a (B), IL-6 (C),
IL-10 (D), and IP-10 (E). The grey box in each graph indicates the relevant cytokine concentration range (geometric mean 6 standard deviation) in
normal healthy donors.
doi:10.1371/journal.pone.0101788.g003
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principal cellular targets and biological effects include activation of
endothelial cells, neutrophil activation, and fever, among others.
IL-10 is an anti-inflammatory cytokine with pleiotropic effects in
immunoregulation and inflammation; it downregulates the
expression of Th1 cytokines, class II MHC antigens, and co-
stimulatory molecules on macrophages. IL-10 also enhances B cell
survival, proliferation, and antibody production. Because IFNc,
TNFa, and IL-10 have a broad spectrum of biological functions,
their role in acute H7N9 infection and their impact on the final
clinical outcome remains to be elucidated.
Influenza antigen-specific antibody responses are critical in
controlling influenza transmission and infection. A lack of pre-
existing antibody responses in the human population is a key
factor for the fast spread of a novel pandemic influenza at a global
scale. Influenza infection is self-limiting to most healthy individuals
due to a quick development of antibody responses. However, there
is a lack of information on how specific antibody responses are
developed in patients who are infected by a novel influenza that
has not previously circulated in the human population. Annual
seasonal influenza immunization is a ‘‘boost’’ to pre-existing
immunity to seasonal influenza in human populations generated
either by subclinical exposure to seasonal influenza in previous
years or via early flu immunizations. In the development of
vaccines against novel H5N1 viruses, two times immunization is
needed to achieve protective antibody responses [48]. A higher
vaccine dose or strong adjuvant may enhance the immunogenicity
of H5N1 vaccines but may not be as effective as twice
immunization. It is important to learn how antibody responses
are generated against an acute influenza infection in a naı¨ve host
who has not been exposed to a subtype of influenza virus such as
H7N9.
In the current study, H7 HA-specific antibody responses were
detected soon after onset of fever and continued to rise until
reaching peak levels within two weeks. Protective antibody
responses appeared at only 2–3 days after the appearance of
binding antibody responses. The most striking result is the
appearance of H7 HA-specific IgM and IgA antibody responses
at the same time as IgG responses; furthermore, slopes of antibody
response curves were similar among three isotypes. The only
difference was that peak level IgA responses were lower than IgM
and IgG peak titers. H7 HA-specific antibody titers of all three
Figure 4. The relationship between significantly elevated serum cytokine levels and fever in H7N9-infected patients. Correlation
between body temperature and each of the significantly elevated cytokines: IFN-c (A), TNF-a (B), IL-6 (C), IL-10 (D), and IP-10 (E) were analyzed. The
solid line in each graph represents the trend line of correlation. Each dot represents one patient at one time point.
doi:10.1371/journal.pone.0101788.g004
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Figure 5. The time frame of significantly elevated serum cytokines at their peak levels, highest fever-, and clearance of H7N9 virus,
as days (median and range) when IFN-c, TNF-a, IL-6, IL-10, and IP-10 are at peak levels and days (median and range) when patients
had the highest fever during hospitalization. Viral clearance is the time point when H7N9 viral RNA became undetectable.
doi:10.1371/journal.pone.0101788.g005
Figure 6. Daily H7 HA-specific IgG responses in H7N9-infected patients during hospitalization. ELISA OD values for daily antibody
responses against H7 HA antigen in individual patients (PT-1–PT-6) with fixed sera dilution at 1:500.
doi:10.1371/journal.pone.0101788.g006
Acute Immune Responses to H7N9 Infection
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major isotypes started to decrease shortly after reaching peak levels
but were still positive at the end of this study.
There is limited information available on patterns of antibody
responses during acute avian influenza infection. While traditional
immunology theory would suggest that IgM antibody responses
occur before IgG responses in a new viral infection, two recent
reports described early detection of IgA responses in acute HIV-1
infection [49,50]. It will be useful to learn how an acute live virus
infection is effective in stimulating simultaneous IgM and IgG
responses, which may help design better vaccines to quickly elicit
powerful and protective IgG antibody responses, without the need
to first elicit IgM responses.
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